Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Sam who wrote (124)	3/19/1998 8:09:00 PM
From: geewiz	Read Replies (2) \| Respond to of 534

Hi Sam, Medi-ject markets a trans-dermal injector that is not suitable for vaccines that have to be delivered to the muscle. Certain drugs are administered in such a manner. Vaccines are not. With the purchase of glucose monitoring technologies Jim said we would now develop a trans-dermal delivery vehicle for insulin of our own. So your question really gets to the heart of the marketing program; when we get into a trans-dermal technology, Medi-ject will be competition. best, art